MetaCap

Lantheus Holdings Inc. Company Profile

NASDAQ: LNTHHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

102.100.00 (0.00%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Lantheus at a glance

Lantheus Holdings Inc. (NASDAQ: LNTH) is a Biotechnology: In Vitro & In Vivo Diagnostic Substances company in the Health Care sector headquartered in Bedford, MA. Lantheus is led by Ms. Mary Anne Heino and employs about 1,193 people. The company's shares have traded publicly since 2015.

At a market capitalization of $6.68 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001521036, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Lantheus do?

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Business description based on the company's public filings.

Company information

Legal name
Lantheus Holdings Inc.
Ticker
NASDAQ: LNTH
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
CEO
Ms. Mary Anne Heino
Employees
1,193
Headquarters
201 Burlington Road, Bedford, MA, United States
Phone
978 671 8001
IPO year
2015
SEC CIK
0001521036
Latest annual report
10-K · Feb 26, 2026

Companies similar to Lantheus

LNTH peer companies
CompanyPrice% ChgMarket capCompare
ORKAOruka Therapeutics Inc.95.81-1.80%$6.50Bvs LNTH
NEOGNeogen Corporation10.55-2.77%$2.30Bvs LNTH
CLDXCelldex Therapeutics Inc.27.42-1.93%$2.15Bvs LNTH
NTLAIntellia Therapeutics Inc.10.00+5.04%$1.40Bvs LNTH
QUITAchieve Life Sciences Inc.5.56-5.28%$573.25Mvs LNTH
QDELQuidelOrtho Corporation8.32-6.73%$570.86Mvs LNTH
MYGNMyriad Genetics Inc.5.46-1.44%$523.74Mvs LNTH
TKNOAlpha Teknova Inc.7.63-2.30%$479.95Mvs LNTH

Related